Skip to main content
. 2019 Sep 10;14(5):603–611. doi: 10.1007/s11523-019-00668-y

Fig. 3.

Fig. 3

Plasma and tissue concentrations (mean ± SD) at 4 (n = 6) and 24 h (n = 6) after the last dose of ME-401 or idelalisib administered orally twice daily for 4 days in an A20 syngeneic model in BALB/c mice. a ME-401 75 mg/kg plasma and tumor concentrations. b ME-401 75 mg/kg plasma and brain concentrations. c ME-401 50 mg/kg plasma and tumor concentrations. d Idelalisib 50 mg/kg plasma and tumor concentrations at 4 h; concentrations at 24 h were below the limit of quantitation